Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices
Issued Date
2022-06-01
Resource Type
eISSN
22113355
Scopus ID
2-s2.0-85130211396
Journal Title
Preventive Medicine Reports
Volume
27
Rights Holder(s)
SCOPUS
Bibliographic Citation
Preventive Medicine Reports Vol.27 (2022)
Suggested Citation
Thongtang N., Sukmawan R., Llanes E.J.B., Lee Z.V. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Preventive Medicine Reports Vol.27 (2022). doi:10.1016/j.pmedr.2022.101819 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85829
Title
Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices
Author(s)
Other Contributor(s)
Abstract
Dyslipidemia is a fundamental risk factor for cardiovascular diseases (CVDs) and can worsen the prognosis, if unaddressed. Lipid guidelines are still evolving as dyslipidemia is affecting newer patient subsets. However, these guidelines are governed by regional demographics and ethnic data. Primary care practitioners (PCPs) are the first to offer treatment, and hence placed early in the healthcare continuum. PCPs shoulder a huge responsibility in early detection of dyslipidemia for primary prevention of future cardiovascular (CV) events. Therefore, as members of Cardiovascular RISk Prevention (CRISP) in Asia network, the authors intend to align and shape-up the daily clinical practice workflow for PCPs and have a goal-directed strategy for managing dyslipidemia. This paper reviews the major international lipid guidelines, namely the American and European guidelines, and the regional guidelines from Indonesia, Malaysia, Philippines, Thailand, and Vietnam to identify their commonalities and heterogeneities. The authors, with a mutual consensus, have put forth, best in-clinic practices for screening, risk assessment, diagnosis, treatment, and management of dyslipidemia, particularly to reduce the overall risk of CV events, especially in the Asian context. The authors feel that PCPs should be encouraged to work in congruence with patients to decide on best possible therapy, which would be a holistic approach, rather than pursuing a “one-size-fits-all” approach. Since dyslipidemia is a dynamic field, accumulation of high-quality evidence and cross-validation studies in the future are warranted to develop best in-clinic practices at a global level.